Table 2.
Some clinical trials of anlotinib in non-small cell lung cancer (NSCLC) for the first line.
| Line(s) of treatment |
Study population |
Study population |
Number of patients |
Median progression-free survival (months) |
ORR (%) | DCR (%) | Reference |
|---|---|---|---|---|---|---|---|
| First line | Patients with EGFR wild-type stage IIIB–IV NSCLC aged more than 70 years | Anlotinib (12 mg, d1–d14/q3w) | 40 | 3.00 | 17.50 | 67.50 | (22) |
| First line | Patients with treatment-naïve and EGFR wild-type stage IIIB–IV NSCLC aged 18 to 75 yeas | Anlotinib (12 mg, d1–d14/q3w) + sintilimab (200 mg, d1/q3w) | 22 | 15.00 | 72.70 | 100.00 | (18) |
| First line | Patients with EGFR-mutated locally advanced and/or metastatic stage IIIB-IV NSCLC aged 18 to 75 years | Anlotinib (12 mg, d1–d14/q3w) + icotinib (125 mg, tid) | 35 | 6.01 | 59.00 | 88.00 | (25) |